F.M.J. Debruyne - Concepedia

Author

F.M.J. Debruyne

Also Known As

A Heerschap, Debruyne, F.M.J., F Debruyne, F M Debruyne, F M J Debruyne, F. DEBRUYNE, F. Debruyne, F. M. Debruyne, F. M. J. DEBRUYNE, F. M. J. Debruyne

739

Publications

20.2K

Citations

H-Index

256

Concepts

All Affiliations

Radboud University Nijmegen Radboud University Medical Center

About

F.M.J. Debruyne is an author at Radboud University Nijmegen specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	47	146	8.4K
2	Health Sciences	19	27	1.7K
3	Engineering	13	15	654
4	Language Studies	3	3	131
5	Education	1	1	15

F.M.J. Debruyne

311

Publications

17.7K

Citations

H-Index

Page 1

	Year	Citations
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Marion J.G. Bussemakers, Adrie van Bokhoven, Gerald W. Verhaegh, PubMed Tumor BiologyUrologyOncologyDd3 GeneGenitourinary Cancer	1999	1.1K
Incidence and Treatment of Complications of Bacillus Calmette-Guerin Intravesical Therapy in Superficial Bladder Cancer Donald L. Lamm, A.P.M. van der Meijden, Álvaro Morales, The Journal of Urology	1992	783
Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study Marloes van der Leest, Erik B. Cornel, Bas Israël, European Urology	2018	740
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial Abdel-Rahmène Azzouzi, S. Vincendeau, Éric Barret, The Lancet Oncology UrologyClin1001 Pcm301Photodynamic TherapyMedicineLow-risk Prostate Cancer	2016	325
4&ndash;Year Follow&ndash;Up Results of a European Prospective Randomized Study on Neoadjuvant Hormonal Therapy prior to Radical Prostatectomy in T2&ndash;3N0M0 Prostate Cancer C Schulman, F.M.J. Debruyne, Gerhard Förster, European Urology UrologySurgical OncologyGenitourinary CancerMedicineRadical Prostatectomy	2000	241
Predictability of Recurrent and Progressive Disease in Individual Patients with Primary Superficial Bladder Cancer Lambertus A. Kiemeney, J.A. Witjes, R.P. Heijbroek, The Journal of Urology	1993	217
POSTERIOR TIBIAL NERVE STIMULATION AS NEUROMODULATIVE TREATMENT OF LOWER URINARY TRACT DYSFUNCTION Michael R. van Balken, Vera Vandoninck, Karel W.H. Gisolf, The Journal of Urology	2001	208
Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Toru Shimazui, Jack A. Schalken, Laurence A. Giroldi, PubMed Tumor BiologyCadherin-associated MoleculesUrologyBladder TumorsCancer Res.	1996	205
Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Anja P. M. Verhagen, F.C.S. Ramaekers, Tilly Aalders, PubMed Cell ProliferationCancer BiologyLuminal Cell-type CytokeratinsCell SpecializationTumor Biology	1992	199
Metastasectomy in Renal Cell Carcinoma: A Multicenter Retrospective Analysis Henk G. van der Poel, Jan A. Roukema, Simon Horenblas, European Urology UrologySurgical OncologyGenitourinary CancerRenal PathologyRenal Cell Carcinoma	1999	198

Page 1